Quantum Genomics Stock

Quantum Genomics EBIT

The EBIT of Quantum Genomics (ALQGC.PA) as of Aug 5, 2026 is -1.47 M EUR. In the previous year, EBIT was -3.14 M EUR — a change of -53.06% (higher).

EBIT

-1.47 MEUR

YoY

-53.06%

Last updated:

In 2026, Quantum Genomics's EBIT was -1.47 M EUR, a -53.06% increase from the -3.14 M EUR EBIT recorded in the previous year.

The Quantum Genomics EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M EUR)
Date
EBIT (M EUR)
Jan 1, 2019
-10.76 base
Jan 1, 2020
-13.86 base
Jan 1, 2021
-19.19 base
Jan 1, 2022
-30.08 base
Jan 1, 2023
-3.14 base
Jan 1, 2024
-1.47 base
Jan 1, 2025 (e)
350.00 base
Jan 1, 2026 (e)
875.00 base
YEAREBIT (M EUR)
2026 est 875.00
2025 est 350.00
2024 -1.47
2023 -3.14
2022 -30.08
2021 -19.19
2020 -13.86
2019 -10.76
2018 -13.60
2017 -10.29
2016 -6.22
2015 -4.31
2014 -2.42
2013 -1.90
2012 -1.06
2011 -1.04
2010 -1.37
2009 -1.43
2008 -1.52
Access this data via the Eulerpool API

Quantum Genomics Revenue

Quantum Genomics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2019
0.00 EUR
-10.76 M EUR
-9.08 M EUR
Jan 1, 2020
1.20 M EUR
-13.86 M EUR
-11.54 M EUR
Jan 1, 2021
116,200.00 EUR
-19.19 M EUR
-16.56 M EUR
Jan 1, 2022
605,000.00 EUR
-30.08 M EUR
-24.94 M EUR
Jan 1, 2023
10,100.00 EUR
-3.14 M EUR
-3.17 M EUR
Jan 1, 2024
0.00 EUR
-1.47 M EUR
-8.89 M EUR
Jan 1, 2025 (e)
153.45 M EUR
350.00 M EUR
565.23 M EUR
Jan 1, 2026 (e)
283.39 M EUR
875.00 M EUR
1.41 B EUR

Quantum Genomics Margins

Quantum Genomics stock margins

The Quantum Genomics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Quantum Genomics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Quantum Genomics.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2019
-14,148.52 %
- %
- %
Jan 1, 2020
-1,005.86 %
-1,151.55 %
-958.68 %
Jan 1, 2021
-15,782.62 %
-16,512.05 %
-14,247.59 %
Jan 1, 2022
-4,776.41 %
-4,972.43 %
-4,121.57 %
Jan 1, 2023
-14,148.52 %
-31,062.38 %
-31,396.04 %
Jan 1, 2024
-14,148.52 %
- %
- %
Jan 1, 2025 (e)
-14,148.52 %
228.09 %
368.35 %
Jan 1, 2026 (e)
-14,148.52 %
308.76 %
498.63 %

Quantum Genomics Stock analysis

What does Quantum Genomics do? Quantum Genomics SA is a French biotechnology company focused on the discovery and development of novel therapies for the treatment of cardiovascular diseases. The company was founded in 2005 in Grenoble, France, where its headquarters are still located. Over 25 employees are currently working on the development of new drugs. The business model of Quantum Genomics SA is based on the research and development of new and innovative solutions for the cardiovascular disease market. The company focuses on a new class of drugs that target the brain to lower blood pressure and treat certain cardiovascular diseases. The goal of these new therapies is to improve the effectiveness of existing treatment methods by directly addressing the causes of the disease. Quantum Genomics SA has established partnerships with renowned research institutes and universities. The collaboration with these institutions aims to accelerate and intensify the research and development of new drugs. Through this collaboration, the company will be able to develop new solutions and therapies to treat cardiovascular diseases at a faster pace. The company is currently working on two main products: Firibastat and the QT-Glutamylcyclotransferase inhibitor. Firibastat is an oral medication developed for the treatment of hypertension. The QT-Glutamylcyclotransferase inhibitor is another medication that is intended to lower blood pressure. These are promising new solutions that can enable Quantum Genomics SA to play a significant role in the cardiovascular disease market. The products of Quantum Genomics SA aim to treat cardiovascular diseases better and more effectively by directly targeting the brain. This aims to reduce the risk of serious complications and side effects that may occur with conventional medications. In recent years, Quantum Genomics SA has received several awards, including the "Innovation Prize" from the French government. These awards demonstrate that the company is on the right track and achieving its goals. Overall, Quantum Genomics SA has a promising business model based on the development of new therapies for the treatment of cardiovascular diseases. With collaborations with renowned research institutes and the development of promising new products, the company is well-positioned to be successful and make significant progress in the growing market of cardiovascular diseases. Quantum Genomics is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Quantum Genomics's EBIT

Quantum Genomics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Quantum Genomics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Quantum Genomics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Quantum Genomics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Quantum Genomics stock

EBIT of Quantum Genomics is -1.47 M EUR in 2026.

EBIT of Quantum Genomics changed from -3.14 M EUR to -1.47 M EUR, representing a -53.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Quantum Genomics since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Quantum Genomics historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Quantum Genomics

All Key Metrics — Quantum Genomics